Evoke Pharma, Inc.

NasdaqCM EVOK

Evoke Pharma, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Evoke Pharma, Inc. Dividends Paid is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024. Dividends paid is cash paid to shareholders as a distribution of profits.

Evoke Pharma, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.

Key data

Date	Dividends Paid	Capital Expenditure	Other Financing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: EVOK

Evoke Pharma, Inc.

CEO	Mr. Matthew J. D'Onofrio MBA
IPO Date	Sept. 25, 2013
Location	United States
Headquarters	420 Stevens Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals

Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Key trends

Past 5 years